Background. Dynamic cardiomyoplasty has been considered to be an effective
method of surgical treatment of patients with end-stage heart failure, and
is an alternative to heart transplantation.
Methods. We critically evaluated the long-term course of 52 patients with d
ilated cardiomyopathy who underwent dynamic cardiomyoplasty and were follow
ed-up for up to 110 months.
Results. Dilated cardiomyopathy was due to undetermined cause in 42 patient
s (80.8%), Chagas disease in 8 (15.4%), viral infection in 1 (1.9%), and pe
ripartum cardiomyopathy in 1 (1.9%). In the nonchagasic group the survival
rates were 79.5% +/- 6.1%, 67.8% +/- 7.1%, 53.7% +/- 8.3%, 49.9% +/- 8.3%,
14.9% +/- 12.2%, and 14.9% +/- 12.2%, respectively, at 12, 24, 48, 60, 80 a
nd 110 months of follow-up. In the chagasic patients the survival rates wer
e 37.5% +/- 17.1%, 12.5% +/- 11.7%, 12.5% +/- 11.7% and 0%, respectively, a
t 12, 24, 48, and 60 months of followup, making chagasic cardiomyopathy a p
ossible contraindication for dynamic cardiomyoplasty.
Conclusions. There was no correlation between the clinical improvement and
hemodynamic data. Ventricular fibrillation was a frequent cause of immediat
e and late death, suggesting the need for prophylactic use of antiarrhythmi
c drugs or implantable cardioverter/defibrillators.
(C) 2000 by The Society of Thoracic Surgeons.